Clinical Trial

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C). The goals of this trial are to evaluate: * if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood * if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood * the safety and tolerability of taking MK-7262 and enlicitide alone and together
Protocol Amendment History 4 changes
notable Trial sites expanded: 12 -> 20 locations 2026-08-04
notable Trial sites expanded: 8 -> 12 locations 2026-07-21
critical Recruitment opened 2026-07-10
notable Trial sites expanded: 0 -> 8 locations 2026-07-10
Trial Details
NCT Number NCT07614984
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Lipoprotein(a)
Enrollment 750 participants
Start Date 2026-06-30
Primary Completion 2027-10-12 (estimated)
Study Completion 2027-10-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-10